Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > CMO Concerns Draw CRL for Navidea’s Lymphoseek

Washington Drug Letter

Sept. 17, 2012 | Vol. 44 No. 37

CMO Concerns Draw CRL for Navidea’s Lymphoseek

The FDA has sent Navidea a complete response letter (CRL) on its Lymphoseek injection, citing concerns over quality control at third-party contract manufacturing facilities.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Nixes Two Gilead HIV Drugs As Standalone Treatments in CRL GSK Ends Impax Partnership Due To Quality-Linked Rytary Delays FDA Rejects Two Gilead HIV Drugs as Standalone Treatments Concerns with CMO Draw CRL for Allergan’s Levadex

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.